<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01149980</url>
  </required_header>
  <id_info>
    <org_study_id>30285</org_study_id>
    <nct_id>NCT01149980</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions</brief_title>
  <official_title>Randomized, 2-way Crossover, Bioequivalence Study of Citalopram Hydrobromide 40 mg Tablets and Celexa 40 mg Tablets Administered as 1 x 40 mg Tablet in Healthy Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a bioequivalence study of Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's
      Laboratories Limited under fed conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      randomized, 2-way crossover; bioequivalence study of citalopram hydrobromide 40 mg tablets
      and celexa 40 mg tablets administered as

      1 x 40 mg tablet in healthy subjects under fed conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">November 2003</completion_date>
  <primary_completion_date type="Actual">November 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUC parameters</measure>
    <time_frame>2 Months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Citalopram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celexa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Celexa 40 mg Tablets of Forest Labs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram Hydrobromide</intervention_name>
    <description>Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited</description>
    <arm_group_label>Citalopram</arm_group_label>
    <arm_group_label>Celexa</arm_group_label>
    <other_name>Celexa Tablets 40 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects enrolled in this study will be members of the community at large. The recruitment
        advertisements may use various media types (e.g. radio, newspaper, Anapharm Inc.Web site,
        Anaphann Inc. volunteers' data base). Subjects must meet all of the following criteria in
        order to be included in the study:

          -  Non-child-bearing potential female or simale, smokers and/or non-smoker, 18 years of
             age and older.

          -  Subjects capable of consent

          -  Non-child-bearing potential female subject:

          -  Post-menopausal state: absence of menses for 12 months prior to drug administration or
             hysterectomy with bilateral oophorectomy at least 6 months prior to drug
             administration.

          -  Surgically sterile: hysterectomy, bilateral oophorectomy, or tubal ligation at least 6
             months prior to drug administration.

        Exclusion Criteria:

          -  Subjects to whom any of the following applies will be excluded from the study:

               -  Clinically significant illnesses within 4 weeks prior to the administration of
                  the study medication.

               -  Clinically significant surgery within 4 weeks prior to the administration of the
                  study medication.

               -  Any clinically significant abnormality found during medical screening.

               -  Any reason which, in the opinion of the Medical Sub-Investigator, would prevent
                  the subject from participating in the study.

               -  Abnormal laboratory tests judged clinically significant.

               -  Positive urine drug screen at screening.

               -  Positive testing for hepatitis B, hepatitis C, or Human Immunodeficiency Virus
                  HIV) at screening.

               -  ECG abnormalities (clinically significant) or vital sign abnormalities (systolic
                  blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower
                  than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm)at screening.

               -  Subjects with Body Mass Index (BMI) 2:30.0.

               -  History of significant alcohol abuse within six months prior to the screening
                  visit or any indication of the regular use of more than fourteen units of alcohol
                  per week (1 Unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol).

               -  History of drug abuse or use of illegal drugs: use of soft drugs (such as
                  marijuana) within 3 months prior to the screening visit or hard drugs (such as
                  cocaine, phencyclidine [PCP]and crack) within 1 year prior to the screening
                  visit.

               -  History of allergic reactions to citalopram hydrobromide or other related drugs.

               -  History of allergic reactions to heparin.

               -  Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of
                  inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids,
                  rifampin/rifabutin; examples of inhibitors: antidepressants, cimetidine,
                  diltiazem, erythromycin, ketoconazole, Mono Amine Oxidase (MAO) inhibitors,
                  neuroleptics, verapamil, quinidine) within 30 days prior to administration of the
                  study medication.

               -  Use of an investigational drug or participation in an investigational study
                  within 30 days prior to administration of the study medication.

               -  Clinically significant history or presence of any clinically significant
                  gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases).
                  Unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney
                  disease, or other conditions known to interfere with the absorption,
                  distribution, metabolism, or excretion of the drug.

               -  Any clinically significant history or presence of clinically significant
                  neurological,endocrinal, cardiovascular, pulmonary, hematologic, immunologic
                  psychiatric or metabolic disease.

               -  Use of prescription medication (including hormone therapy) within 14 days prior
                  to administration of study medication or over-the-counter products (including
                  natural food supplements, vitamins, garlic as a supplement) within 7 days prior
                  to administration of study medication, except for topical products without
                  systemic absorption.

               -  Smoking more than 25 cigarettes per day.

               -  Any food allergy, intolerance, restriction or special diet that could, in the
                  opinion of the Medical Sub-Investigator, contraindicate the subject's
                  participation in this study.

               -  A depot injection or an implant of any drug within 3 months prior to
                  administration of study medication.

               -  Donation of plasma (500 mL) within 7 days prior to drug administration. Donation
                  or loss of whole blood prior to administration of the study medication as
                  follows:

               -  less than 300 mL of whole blood within 30 days,

               -  300 mL to 500 mL of whole blood within 45 days or

               -  more than 500 mL of whole blood within 56 days prior to drug administration.

               -  Consumption of food or beverages containing grapefruit (e.g. fresh, canned or
                  frozen)within 7 days prior to administration of the study medication.

               -  History of seizure disorder or bipolar affective disorder.

               -  Active psychiatric diagnosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit Girard, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm. Clinical Laboratory</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anapharm</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2010</study_first_submitted>
  <study_first_submitted_qc>June 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2010</study_first_posted>
  <last_update_submitted>June 23, 2010</last_update_submitted>
  <last_update_submitted_qc>June 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr.Ramakrishna Banagaru</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Crossover</keyword>
  <keyword>Citalopram</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

